NEWS RELEASE

NYSE MKT to Suspend Trading Immediately in ERBA Diagnostics, Inc. and Commence Delisting Proceedings

9/29/2016

NEW YORK, September 29, 2016 – NYSE MKT LLC (“NYSE MKT” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ERBA Diagnostics, Inc. (the "Company") — ticker symbol ERB —from the Exchange. Trading in the Company’s common stock will be suspended immediately.

NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Sections 134 and 1101 of the NYSE MKT Company Guide. NYSE Regulation notes that the Company will not be able to complete its Form 10-K for the fiscal year ended December 31, 2015 and Form 10-Q filings for the periods ended September 30, 2015, March 31, 2016 and June 30, 2016 by the previously granted plan period end date of November 25, 2016.

The Company has a right to a review of staff’s determination to delist the common stock by a committee of the Board of Directors of the Exchange. The NYSE MKT will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Company Contact:

Mohan Gopalkrishnan
Chief Executive Officer

Tel: (305) 418-2320